Concepedia

Author

Marco Salvini

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoORCID

Also Known As

C. Cisari, M SALVINI, M Salvini, M. Salvini, Marco Salvini

71

Publications

1.5K

Citations

15

H-Index

18

Concepts

All Affiliations

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoFondazione IRCCS Istituto Nazionale dei TumoriUniversity of TurinOspedale Policlinico San MartinoFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
MS

About

Marco Salvini is an author at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

73

2

Pharmacology

2

2

29

3

Health Sciences

1

1

10

4

Immunology

1

1

44

5

Marrow Transplantation

1

1

44

Marco Salvini

×

14

Publications

1.2K

Citations

11

H-Index

YearCitations

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti, Chiara Cattaneo, Luca Arcaini,

The Lancet Haematology

2020

551

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano, Jon Salmanton‐García, Francesco Marchesi,

Journal of Hematology & Oncology

2021

312

COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies

Francesco Passamonti, Alessandra Romano, Marco Salvini,

British Journal of Haematology

2021

65

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Carlo Visco, Luigi Marcheselli, Roberto Mina,

Blood Advances

2021

56

Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci,

Leukemia

2016

44

Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

Alessandra Larocca, Marco Salvini, Lorenzo De Paoli,

Blood

2018

35

Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy

Giulia Bruno, Sara Bringhen, Ilaria Maffei,

Cancers

2019

25

Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy

Andrea Iannaccone, Giulia Bruno, Agnese Ravera,

High Blood Pressure & Cardiovascular Prevention

2018

19

Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction

Anna Astarita, Giulia Mingrone, Lorenzo Airale,

Cancers

2021

15

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients

Giulia Mingrone, Anna Astarita, Lorenzo Airale,

Frontiers in Cardiovascular Medicine

2021

13

Page 1